Stephens Consulting’s Enliven Therapeutics ELVN Stock Holding History

Stephens Consulting’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20	Closed	-$394	–	1435
2025 Q1	$394	Buy	+20	New	+$430	﹤0.01%	1069

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Stephens Consulting's ELVN Position: Q2 2025 in Review

Stephens Consulting sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 20 shares — an estimated $394 sold.

Stephens Consulting first reported a position in ELVN in Q1 2025 and held it in 1 quarter. The position peaked at $394 in Q1 2025. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

Stephens Consulting reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 20 Enliven Therapeutics shares in Q2 2025, an estimated $394.
Stephens Consulting first reported a position in Enliven Therapeutics in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Enliven Therapeutics position peaked at $394 in Q1 2025.
124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.